Uncategorized

Protein targets tissue factor, angiogenesis in CNV related to AMD

by Healio ophthalmology • 2016/02/17 • 0 Comments

MIAMI — A protein that targets tissue factor in neovascular age-related macular degeneration was well tolerated in a phase 1 study, a speaker told colleagues here. Carl D. Regillo, MD, reviewed results of a phase 1 study of ICON-1 (Iconic Therapeutics) in the treatment of neovascular AMD at Angiogenesis, Exudation, and Degeneration 2016.

Full Story →

← Aerie Pharmaceuticals Reports Positive RhopressaTM QD (netarsudil ophthalmic solution) 0.02% 12 Month Interim Safety Results for Rocket 2

Senate committee proposes more efficient approval of medical devices →

Post navigation